

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

Control of the leishmaniases

Report of a
WHO Expert Committee

World Health Organization
Technical Report Series
793



World Health Organization, Geneva 1990

WHO Library Cataloguing in Publication Data

WHO Expert Committee on the Control of the Leishmaniasis
Control of the leishmaniasis: report of a WHO expert committee.

(World Health Organization technical report series ; 793)

1. Leishmaniasis – prevention and control I. Title II. Series

ISBN 92 4 120793 0
ISSN 0512-3054

(NLM Classification: WR 350)

© World Health Organization 1990

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

89/8325 – Schüler SA – 7000

CONTENTS

	Page
1. Introduction.....	9
2. The leishmaniases in man.....	10
2.1 Clinical forms.....	10
2.1.1 Old World visceral leishmaniasis.....	10
2.1.2 Old World cutaneous leishmaniasis.....	12
2.1.3 Old World diffuse cutaneous leishmaniasis	13
2.1.4 New World visceral leishmaniasis	13
2.1.5 New World cutaneous leishmaniasis	13
2.1.6 New World diffuse cutaneous leishmaniasis.....	15
2.1.7 New World mucocutaneous leishmaniasis	15
2.2 Pathology	16
2.2.1 General pathology	16
2.2.2 Host-parasite relationship and immunology	17
2.2.3 Specific pathology	18
2.3 Parasitology	21
2.3.1 Identification methods	21
2.3.2 Identification criteria	23
2.3.3 Taxonomy.....	24
2.4 Reservoir hosts.....	24
2.4.1 Definition.....	24
2.4.2 Factors that influence reservoir capacity.....	26
2.4.3 Incrimination of reservoir hosts	26
2.4.4 Domestic and peridomestic reservoir hosts	27
2.4.5 Wild reservoir hosts of the Old World.....	28
2.4.6 Wild reservoir hosts of the New World	31
2.5 Vectors	33
2.5.1 Taxonomy.....	33
2.5.2 Identification criteria	33
2.5.3 Biology.....	35
2.5.4 Incrimination of vectors	38
2.5.5 Vector capacity.....	40
2.6 Epidemiological aspects	41
2.6.1 Transmission sites and human behaviour	41
2.6.2 Population movements	43
2.6.3 Environmental changes.....	44
2.6.4 Periodic fluctuations	45
2.6.5 Quantitative epidemiology.....	45
2.6.6 Effect of malaria control programmes	46
3. Control methods.....	47
3.1 Diagnosis.....	47
3.1.1 Visceral leishmaniasis	47
3.1.2 Cutaneous leishmaniasis	48
3.1.3 Mucocutaneous leishmaniasis.....	49
3.2 Passive case detection	49

3.3 Active medical surveillance.....	50
3.3.1 Visceral leishmaniasis	50
3.3.2 Cutaneous leishmaniasis	50
3.4 Treatment.....	50
3.4.1 Visceral leishmaniasis	51
3.4.2 Cutaneous leishmaniasis	52
3.4.3 Mucocutaneous leishmaniasis.....	54
3.5 Control of reservoir hosts.....	55
3.5.1 Man as reservoir host.....	56
3.5.2 Domestic and commensal animal reservoir hosts	56
3.5.3 Wild animal reservoir hosts.....	57
3.6 Sandfly control.....	60
3.6.1 Evaluation of anti-sandfly measures.....	60
3.6.2 Chemical control	61
3.6.3 Environmental management.....	63
3.6.4 Self-protection.....	63
3.7 Integrated approaches.....	64
3.8 Emergency measures in epidemics	64
3.9 Immunization.....	65
4. Geographical distribution of leishmaniasis by country and territory.....	66
5. Control strategies by nosogeographical entities.....	96
5.1 Visceral leishmaniasis caused by <i>L. donovani</i> , <i>L. infantum</i> and <i>L. chagasi</i>	96
5.1.1 Visceral leishmaniasis in the Indian subcontinent caused by <i>L. donovani</i>	96
5.1.2 Visceral leishmaniasis in East Africa and the south-west Arabian peninsula caused by <i>L. donovani</i> and <i>L. infantum</i>	98
5.1.3 Foci of visceral leishmaniasis caused by <i>L. infantum</i> and <i>L. chagasi</i> with known or assumed canine reservoir hosts	99
5.2 Anthroponotic cutaneous leishmaniasis caused by <i>L. tropica</i>	102
5.3 Zoonotic cutaneous leishmaniasis caused by <i>L. major</i>	104
5.4 Zoonotic cutaneous leishmaniasis of Eastern African highlands caused by <i>L. aethiopica</i>	107
5.5 Uta caused by <i>L. peruviana</i>	107
5.6 Cutaneous leishmaniasis caused by <i>L. guyanensis</i>	109
5.7 Cutaneous and mucocutaneous leishmaniasis caused by <i>L. panamensis</i>	110
5.8 Cutaneous and mucocutaneous leishmaniasis caused by <i>L. braziliensis</i>	111
5.9 Cutaneous leishmaniasis caused by the <i>L. mexicana</i> complex	113
6. Organization of control.....	118
6.1 Control of leishmaniasis as part of primary health care.....	118
6.1.1 Local responsibility.....	118
6.1.2 Appropriate communications	118
6.1.3 Realistic operational level.....	119
6.1.4 The time factor.....	120
6.2 Definition of national plans.....	120
6.2.1 Purpose and use of national control programmes	121
6.2.2 Preliminary inventory	121
6.2.3 Definition of a control strategy.....	122

6.2.4 Intersectoral coordination	122
6.2.5 Formal adoption.....	124
7. International coordination	124
7.1 Reporting.....	124
7.2 Intercountry programmes	124
7.3 International standards.....	125
8. Health education and training	126
8.1 Health education.....	126
8.2 Training.....	127
9. Research	128
9.1 Field research	128
9.2 Laboratory research.....	128
10. Recommendations	129
Acknowledgements.....	130
References	131
Annex 1. Labelling of <i>Leishmania</i> isolates, identification centres and sources of standards	132
Annex 2. Methods for the isolation and cryopreservation of <i>Leishmania</i>	139
Annex 3. Mathematical model for determining the mean level of transmission of zoonotic cutaneous leishmaniasis caused by <i>L. major</i>	151
Annex 4. Procedures for splenic aspiration and grading of parasites	153
Annex 5. Ball-point pen technique for measuring induration of skin-test reactions	156
Annex 6. Costs of drugs in current use for the treatment of leishmaniasis, excluding hospital costs and other local costs	157
Annex 7. Cost comparison of insecticides as applied in residual spraying, excluding operational costs	158
 <i>Tables</i>	
Table 1. Methods for identifying <i>Leishmania</i>	22
Table 2. Proven vectors of human leishmaniasis.....	34
Table 3. Distribution of leishmaniasis by country and territory	67
Table 4. Approaches to leishmaniasis control by nosogeographical entity..	114
Table 5. The 11 main approaches to control, summarized by country or territory.....	115
Table 6. Possible distribution of tasks for the control of leishmaniasis among different health sectors.....	119
Table 7. Budget frame for a national programme for the control of leishmaniasis	123
Table 8. Steps in the development of a national programme for the control of leishmaniasis.....	125
Table A1.1 Generic codes for labelling of <i>Leishmania</i> isolates according to the international code	133
Table A1.2 ISO codes for countries or territories where autochthonous cases of leishmaniasis are known or suspected, for use in the labelling of <i>Leishmania</i> isolates	135

Table A1.3 <i>Leishmania</i> reference strains	136
Table A1.4 Centres that have the facilities for identification of <i>Leishmania</i> isolates, and which can accept material for identification	137
<i>Figures</i>	
Fig. 1. Taxonomy of <i>Leishmania</i>	25
Fig. 2. Some animal reservoir hosts of Old and New World leishmaniasis....	29
Fig. 3. Schematic life cycle of a phlebotomine sandfly	36
Fig. 4. Distribution of visceral leishmaniasis in the Old and New World.....	97
Fig. 5. Distribution of Old World cutaneous leishmaniasis due to <i>L. tropica</i> and <i>L. aethiopica</i>	103
Fig. 6. Distribution of Old World cutaneous leishmaniasis due to <i>L. major</i> ..	105
Fig. 7. Distribution of cutaneous and mucocutaneous leishmaniasis in the New World.....	108

ABBREVIATIONS

The following abbreviations are used in this report:

ACL	anthroponotic cutaneous leishmaniasis
AVL	anthroponotic visceral leishmaniasis
CL	cutaneous leishmaniasis
DCL	diffuse cutaneous leishmaniasis
ELISA	enzyme-linked immunosorbent assay
LR	leishmaniasis recidivans
MCL	mucocutaneous leishmaniasis
NWCL	New World cutaneous leishmaniasis
NWVL	New World visceral leishmaniasis
PKDL	post-kala-azar dermal leishmaniasis
VL	visceral leishmaniasis
ZCL	zoonotic cutaneous leishmaniasis
ZVL	zoonotic visceral leishmaniasis

WHO EXPERT COMMITTEE ON THE CONTROL
OF THE LEISHMANIASES

Geneva, 6-10 February 1989

*Members**

- Dr R.W. Ashford, Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, England
Dr S. Belazzoug, Chief, Leishmaniasis Unit, Department of Parasitology, Pasteur Institute of Algiers, Algiers, Algeria (*Rapporteur*)
Dr R. Killick-Kendrick, Imperial College of Science and Technology, Imperial College Field Station, Ascot, England (*Chairman*)
Dr V. Neronov, USSR Committee for the UNESCO Programme on Man and the Biosphere, Moscow, Union of Soviet Socialist Republics
Dr S. Qubain, Director, Directorate of Primary Health Care, Ministry of Health, Amman, Jordan
Professor J.A. Rioux, Laboratory of Medical Ecology and Parasite Pathology, Faculty of Medicine, Montpellier, France
Dr Y. Schlein, Department of Parasitology, Hadassah Medical School, Hebrew University of Jerusalem, Jerusalem, Israel
Dr V. Sergiev, Director, Martsinovsky Institute of Medical Parasitology and Tropical Medicine, Moscow, Union of Soviet Socialist Republics
Professor C.P. Thakur, Department of Medicine, Patna Medical College, Patna, India
Dr B.C. Walton, Lake Heritage, Gettysburg, PA, United States of America
Dr J.B. Were, Clinical Research Centre, Kenya Medical Research Institute, Nairobi, Kenya
Dr D.G. Young, Assistant Research Scientist, Department of Entomology, University of Florida, Gainesville, FL, United States of America

Secretariat

- Dr P. Desjeux, Medical Officer, Trypanosomiasis and Leishmaniasis, Parasitic Diseases Programme, WHO, Geneva, Switzerland
Mr Guan Li Ren, Assistant Research Fellow, Department of Epidemiology, Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shanghai, China (*Temporary Adviser*)
Dr F. Modabber, Secretary of the Steering Committee on Leishmaniasis, UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, WHO, Geneva, Switzerland
Dr A. Nadim, School of Public Health and Institute of Public Health, Tehran, Islamic Republic of Iran (*Temporary Adviser*)
Dr P. de Raadt, Chief Medical Officer, Trypanosomiasis and Leishmaniasis, Parasitic Diseases Programme, WHO, Geneva, Switzerland (*Secretary*)

* Unable to attend: Dr M.C.A. Marzochi, Director, Department of Biological Sciences, National School of Public Health of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30759

